FindTrial
Sign In

Fairness, poverty, and cost-effectiveness impact of two doses of corticosteroid injection given to pregnant women at risk of delivering before term

A three-arm, parallel group, double-blind, placebo-controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes: Impact on equity, poverty, and cost-effectiveness analysis (EQUIFINANCE ACTION-III) - EQUIFINANCE ACTION-III

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055525
Enrollment
1800
Registered
2023-07-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P220- Respiratory distress syndrome of newborn

Interventions

Intervention1: Dexamethasone phosphate 4x6mg q12h (Dexa-4x6mg) regimen: A single course of 6mg IM dexamethasone sodium phosphate administered every 12 hours, to a total of four doses (starting immedia

Sponsors

Translational Health Science and Technology Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The study population includes pregnant women coming to the hospital for delivery in the late preterm period (enrolled in the main ACTION III trial) and their newborn.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Proportion of families with Catastrophic Healthcare Expenditure (CHE) due to in-patient and out-patient health care seeking for the ACTION III babyTimepoint: Proportion of families with Catastrophic Healthcare Expenditure (CHE) due to in-patient and out-patient health care seeking for the ACTION III baby—

Secondary

MeasureTime frame
Cost per additional disability-adjusted life yearTimepoint: Enrolment to 28-days post-partum;Equity impactTimepoint: Enrolment to 28-days post-partum;Extended cost effectivenessTimepoint: Enrolment to 28-days post-partum;ImpoverishmentTimepoint: Enrolment to 28-days post-partum;Incremental Cost-Effectiveness RatioTimepoint: Enrolment to 28-days post-partum;Mean out-of-pocket expenditureTimepoint: Enrolment to 28-days post-partum—

Countries

India

Contacts

Public ContactShinjini Bhatnagar

Maternal & Child health, Translational Health Science Technology Institute

nitya.wadhwa@thsti.res.in01292876342

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026